Tegretol Oral Suspension 2%: Update to the posology, method of administration, and limitation of use in neonates

A Dear Healthcare Professional Letter has been issued by Novartis (Singapore) Pte Ltd to inform healthcare professionals of updates to the posology, method of administration, and limitation of use in neonates with Tegretol Oral Suspension 2% (OS). The revised maximum daily dose for Tegretol OS is recommended to be limited to 1200 mg/day. This recommendation is initiated to limit the amount of sorbitol intake given current constraints in sourcing sorbitol batches compliant with appropriate specifications. In addition, Tegretol OS is no longer recommended for neonates (below 4 weeks of age for term babies or 44 weeks post-menstrual age for pre-term babies) due to the amount of propylene glycol in this formulation. Please refer to the letter for details.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg ↗ (opens in new tab) and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.